The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy

References

• Aggarwal P, Hall JB, Mcleland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev, 2009;61:428–37
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Nicolini G, Bizzi A, Spinola M, Singh D. Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy Asthma Proc, 2012;33:140–4
   PubMed Web of Science ®Google Scholar
• Berishvili TA. PAS inhalation therapy of respiratory tuberculosis in the sanatorium LIBANI; preliminary communication. Probl Tuberk, 1954;4:69–70
   PubMedGoogle Scholar
• Brennan MJ, Clagett B, Fitzgerald H, Chen V, Williams A, Izzo AA, Barker LF. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine, 2012;30:2811–23
   PubMed Web of Science ®Google Scholar
• Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: A meta-analysis of the literature. Clin Infect Dis, 2000;31:S64–7
   PubMed Web of Science ®Google Scholar
• Carvalho TC, Peters JI, Williams RO III. Influence of particle size on regional lung deposition – what evidence is there? Int J Pharm, 2011;406:1–10
   PubMed Web of Science ®Google Scholar
• Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H, Dawson KA, Linse S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA, 2007;104:2050–5
   PubMed Web of Science ®Google Scholar
• Chan JG, Chan HK, Prestidge CA, Denman JA, Young PM, Traini D. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur J Pharm Biopharm, 2012;83:285--92
   PubMedGoogle Scholar
• Dahl AR, Lewis JL. Respiratory tract uptake of inhalants and metabolism of xenobiotics. Annu Rev Pharmacol Toxicol, 1993;33:383–407
   PubMedGoogle Scholar
• Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: A new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother, 2013;57:2613–19
   PubMed Web of Science ®Google Scholar
• Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother, 2012;56:3027–31
   PubMed Web of Science ®Google Scholar
• Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science, 1997;276:1868–71
   PubMed Web of Science ®Google Scholar
• Eixarch H, Haltner-Ukomadu E, Beisswenger C, Bock U. Drug delivery to the lung: Permeability and physicochemical characteristics of drugs as the basis for a pulmonary biopharmaceutical classification system (pBCS). J Epithelial Biol Pharmacol, 2010;3:1–14
   Google Scholar
• Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang T, Holst P, Thomsen AR, Andersen P, Dietrich J. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One, 2009;4:e5139
   PubMed Web of Science ®Google Scholar
• Fiegel J, Garcia-Contreras L, Thomas M, Verberkmoes J, Elbert K, Hickey A, Edwards D. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res, 2008;25:805–11
   PubMed Web of Science ®Google Scholar
• Fox W. Whither short-course chemotherapy? Br J Dis Chest, 1981;75:331–57
   PubMedGoogle Scholar
• Garcia-Contreras L, Fiegel J, Telko M, Elbert K, Hawi A, Thomas M, Verberkmoes J, Germishuizen W, Fourie P, Hickey A, Edwards D. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother, 2007;51:2830–6
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Muttil P, Fallon JK, Kabadi M, Gerety R, Hickey AJ. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. Antimicrob Agents Chemother, 2012;56:2612–18
   PubMed Web of Science ®Google Scholar
• Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, Verberkmoes JL, Elbert KJ, Hickey AJ, Edwards DA. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother, 2010;54:1436–42
   PubMed Web of Science ®Google Scholar
• Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatr Pulmonol, 2007;42:307–13
   PubMed Web of Science ®Google Scholar
• Gonzalez-Juarrero M, O’Sullivan MP. Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells. Tuberculosis (Edinb), 2011;91:86–92
   PubMedGoogle Scholar
• Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med, 1994;150:1256–61
   PubMed Web of Science ®Google Scholar
• Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol, 1999;56:1329–39
   PubMed Web of Science ®Google Scholar
• Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest, 1999;104:147–53
   PubMed Web of Science ®Google Scholar
• Hanif SN, Garcia-Contreras L. Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front Cell Infect Microbiol, 2012;2:118
   PubMed Web of Science ®Google Scholar
• Hassan MS, Lau RW. Effect of particle shape on dry particle inhalation: Study of flowability, aerosolization, and deposition properties. AAPS PharmSciTech, 2009;10:1252–62
   PubMed Web of Science ®Google Scholar
• Hickey AJ, Misra A, Fourie PB. Dry powder antibiotic aerosol product development: Inhaled therapy for tuberculosis. J Pharm Sci, 2013;102:3900–7
   PubMed Web of Science ®Google Scholar
• Hirata T, Saito H, Tomioka H, Sato K, Jidoi J, Hosoe K, Hidaka T. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1995;39:2295–303
   PubMed Web of Science ®Google Scholar
• Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma G, Makino K, Terada H. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release, 2010;142:339–46
   PubMed Web of Science ®Google Scholar
• Hofmann W. Modelling inhaled particle deposition in the human lung – A review. J Aerosol Sci, 2011;42:693–724
   Web of Science ®Google Scholar
• Hwang SM, Kim DD, Chung SJ, Shim CK. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release, 2008;129:100–6
   PubMed Web of Science ®Google Scholar
• ICMR. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. Indian J Med Res, 1999;110:56–69
   Google Scholar
• Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet, 1994;26:144–60
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol, 2003;56:588–99
   PubMed Web of Science ®Google Scholar
• Li X, Manjunatha UH, Goodwin MB, Knox JE, Lipinski CA, Keller TH, Barry CE III, Dowd CS. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo [2,1-b][1,3]oxazines, analogues of PA-824. Bioorg Med Chem Lett, 2008;18:2256–62
   PubMed Web of Science ®Google Scholar
• Lipworth B. Targeting the small airways asthma phenotype: If we can reach it, should we treat it? Ann Allergy Asthma Immunol, 2013;110:233–9
   PubMed Web of Science ®Google Scholar
• Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA, 2008;105:14265–70
   PubMed Web of Science ®Google Scholar
• Martonen T. Deposition of inhaled particulate matter in the upper respiratory-tract, larynx, and bronchial airways – A mathematical-description. J Toxicol Environ Health, 1983a;12:787–800
   PubMed Web of Science ®Google Scholar
• Martonen T. On the fate of inhaled particles in the human – A comparison of experimental-data with theoretical computations based on a symmetric and asymmetric lung. Bull Math Biol, 1983b;45:409–24
   PubMed Web of Science ®Google Scholar
• Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, Fourie PB, Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb), 2011;91:71–81
   PubMed Web of Science ®Google Scholar
• Mitchison D, Davies G. The chemotherapy of tuberculosis: Past, present and future. Int J Tuberc Lung Dis, 2012;16:724–32
   PubMed Web of Science ®Google Scholar
• Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis, 2000;4:796–806
   PubMed Web of Science ®Google Scholar
• Mitchison DA, Fourie PB. The near future: Improving the activity of rifamycins and pyrazinamide. Tuberculosis (Edinb), 2010;90:177–81
   PubMed Web of Science ®Google Scholar
• Mortensen NP, Hurst GB, Wang W, Foster CM, Nallathamby PD, Retterer ST. Dynamic development of the protein corona on silica nanoparticles: Composition and role in toxicity. Nanoscale, 2013;5:6372--80
   Google Scholar
• Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci, 2007;32:140–50
   PubMed Web of Science ®Google Scholar
• Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm Res, 2009;26:2401–16
   PubMed Web of Science ®Google Scholar
• O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol, 2013;31:475–527
   PubMed Web of Science ®Google Scholar
• O’Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization. Pharm Res, 2000;17:955–61
   PubMed Web of Science ®Google Scholar
• Palazzo F, Giovagnoli S, Schoubben A, Blasi P, Rossi C, Ricci M. Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex. Int J Pharm, 2013;440:273–82
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother, 2005a;55:430–5
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb), 2005b;85:227–34
   PubMed Web of Science ®Google Scholar
• Park JH, Jin HE, Kim DD, Chung SJ, Shim WS, Shim CK. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm, 2013;441:562–9
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov, 2007;6:67–74
   PubMed Web of Science ®Google Scholar
• Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol, 1996;33:167–75
   PubMed Web of Science ®Google Scholar
• Rojanarat W, Changsan N, Tawithong E, Pinsuwan S, Chan HK, Srichana T. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int J Mol Sci, 2011;12:4414–34
   PubMed Web of Science ®Google Scholar
• Rojanarat W, Nakpheng T, Thawithong E, Yanyium N, Srichana T. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv, 2012;19:334–45
   PubMed Web of Science ®Google Scholar
• Roy CJ, Sivasubramani SK, Dutta NK, Mehra S, Golden NA, Killeen S, Talton JD, Hammoud BE, Didier PJ, Kaushal D. Aerosolized gentamicin reduces the burden of tuberculosis in a murine model. Antimicrob Agents Chemother, 2012;56:883–6
   PubMedGoogle Scholar
• Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Del Rev, 2006;58:1030–60
   PubMed Web of Science ®Google Scholar
• Schoubben A, Blasi P, Marenzoni ML, Barberini L, Giovagnoli S, Cirotto C, Ricci M. Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization. Eur J Pharm Biopharm, 2013;83:388–95
   PubMed Web of Science ®Google Scholar
• Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother, 2007;51:576–82
   PubMed Web of Science ®Google Scholar
• Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res, 2001;18:1405–10
   PubMed Web of Science ®Google Scholar
• Stover CK, Warrener P, Vandevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000;405:962–6
   PubMed Web of Science ®Google Scholar
• Suarez S, O’Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother, 2001a;48:431–4
   PubMed Web of Science ®Google Scholar
• Suarez S, O’Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model. Pharm Res, 2001b;18:1315–19
   PubMed Web of Science ®Google Scholar
• Sung JC, Garcia-Contreras L, Verberkmoes JL, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother, 2009;53:1338–43
   PubMed Web of Science ®Google Scholar
• Swift DL. Generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis, 1980;122:71–7
   PubMed Web of Science ®Google Scholar
• Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care, 2005;50:1209–27
   PubMedGoogle Scholar
• Tsapis N, Bennett D, O’Driscoll K, Shea K, Lipp M, Fu K, Clarke R, Deaver D, Yamins D, Wright J, et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis, 2003;83:379–85
   PubMed Web of Science ®Google Scholar
• Ulrik CS, Lange P. Targeting small airways in asthma: Improvement in clinical benefit? Clin Respir J, 2011;5:125–30
   PubMedGoogle Scholar
• Upton RN, Doolette DJ. Kinetic aspects of drug disposition in the lungs. Clin Exp Pharmacol Physiol, 1999;26:381–91
   PubMed Web of Science ®Google Scholar
• Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, Gupta P, Gupta UD, Cholo M, Anderson R, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother, 2013;57:1050–2
   PubMed Web of Science ®Google Scholar
• Verma RK, Singh AK, Mohan M, Agrawal AK, Misra A. Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems. Ther Deliv, 2011;2:753–68
   PubMedGoogle Scholar
• Vroman L. Effect of adsorbed proteins on wettability of hydrophilic and hydrophobic solids. Nature, 1962;196:476
   PubMed Web of Science ®Google Scholar
• Vroman L, Adams AL, Fischer GC, Munoz PC. Interaction of high molecular-weight kininogen, factor-XII, and fibrinogen in plasma at interfaces. Blood, 1980;55:156–9
   PubMed Web of Science ®Google Scholar
• Wang C, Muttil P, Lu D, Beltran-Torres AA, Garcia-Contreras L, Hickey AJ. Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines. AAPS J, 2009;11:139–47
   PubMed Web of Science ®Google Scholar
• Wanger A, Mills K. Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using Etest. J Clin Microbiol, 1996;34:1672–6
   PubMed Web of Science ®Google Scholar
• WHO. 2012. Global Tuberculosis Report 2012
   Google Scholar